2.1
Belantamab mafodotin (Blenrep, GlaxoSmithKline) 'in combination with bortezomib and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy'.
2 Information about belantamab mafodotin with bortezomib and dexamethasone
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for belantamab mafodotin.
Price
2.3
The list price for belantamab mafodotin is £16,848 per 100‑mg vial and £11,784 per 70‑mg vial (excluding VAT; company submission).
2.4
The company has a commercial arrangement. This makes belantamab mafodotin available to the NHS with a discount. The size of the discount is commercial in confidence.
Sustainability
2.5
For information, the Carbon Reduction Plan for UK carbon emissions is available on GlaxoSmithKline's UK webpage.